enGene (NASDAQ:ENGN) Shares Gap Down to $15.74

enGene Holdings Inc. (NASDAQ:ENGN)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $15.74, but opened at $15.34. enGene shares last traded at $15.34, with a volume of 1,122 shares trading hands.

Analyst Ratings Changes

A number of brokerages have commented on ENGN. Leerink Partnrs restated an “outperform” rating on shares of enGene in a research report on Tuesday, February 20th. SVB Leerink assumed coverage on shares of enGene in a report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price target for the company. UBS Group initiated coverage on shares of enGene in a research report on Thursday, March 28th. They issued a “buy” rating and a $37.00 target price for the company. Guggenheim started coverage on shares of enGene in a report on Monday, April 15th. They set a “buy” rating and a $34.00 price target on the stock. Finally, Morgan Stanley began coverage on enGene in a report on Friday, March 8th. They set an “overweight” rating and a $40.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $35.50.

enGene Trading Up 4.8 %

The firm has a 50 day simple moving average of $15.97.

Hedge Funds Weigh In On enGene

Several hedge funds have recently bought and sold shares of ENGN. Fcpm Iii Services B.V. acquired a new stake in shares of enGene in the fourth quarter worth about $80,097,000. Goldman Sachs Group Inc. bought a new position in shares of enGene in the 4th quarter valued at approximately $346,000. Blue Owl Capital Holdings LP acquired a new stake in enGene in the 4th quarter worth approximately $11,397,000. Omega Fund Management LLC bought a new stake in enGene during the fourth quarter worth approximately $10,441,000. Finally, BVF Inc. IL acquired a new position in enGene during the fourth quarter valued at approximately $20,777,000. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.